S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
OTCMKTS:ALPMY

Astellas Pharma Stock Forecast, Price & News

$16.56
+0.29 (+1.78 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.48
Now: $16.56
$16.58
50-Day Range
$14.19
MA: $15.08
$15.95
52-Week Range
$12.48
Now: $16.56
$18.43
Volume137,217 shs
Average Volume86,419 shs
Market Capitalization$30.83 billion
P/E Ratio24.00
Dividend Yield1.78%
Beta0.63
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. It offers XTANDI, an androgen receptor signaling inhibitor for the treatment of prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ transplant rejection. The company also provides Vesicare for OAB treatment; Eligard for prostate cancer treatment; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical collaboration agreement with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and Cytokinetics, Incorporated, as well as an agreement with BANDAI NAMCO Entertainment Inc. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Astellas Pharma logo

MarketRank

Overall MarketRank

1.54 out of 5 stars

Medical Sector

244th out of 1,926 stocks

Pharmaceutical Preparations Industry

122nd out of 773 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ALPMY
CUSIPN/A
CIKN/A
Phone813-3244-3000
Employees15,883

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.97 billion
Cash Flow$1.33 per share
Book Value$6.28 per share

Profitability

Net Income$1.80 billion

Miscellaneous

Outstanding Shares1,861,790,000
Market Cap$30.83 billion
Next Earnings Date1/29/2021 (Estimated)
OptionableNot Optionable
$16.56
+0.29 (+1.78 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Astellas Pharma (OTCMKTS:ALPMY) Frequently Asked Questions

How has Astellas Pharma's stock been impacted by Coronavirus?

Astellas Pharma's stock was trading at $15.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALPMY shares have increased by 5.3% and is now trading at $16.56.
View which stocks have been most impacted by COVID-19
.

Is Astellas Pharma a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Astellas Pharma stock.
View analyst ratings for Astellas Pharma
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Astellas Pharma?

Wall Street analysts have given Astellas Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Astellas Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Astellas Pharma's next earnings date?

Astellas Pharma is scheduled to release its next quarterly earnings announcement on Friday, January 29th 2021.
View our earnings forecast for Astellas Pharma
.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) issued its quarterly earnings data on Friday, October, 30th. The company reported $0.28 earnings per share (EPS) for the quarter. The firm had revenue of $2.91 billion for the quarter. Astellas Pharma had a return on equity of 13.24% and a net margin of 11.03%.
View Astellas Pharma's earnings history
.

Is Astellas Pharma a good dividend stock?

Astellas Pharma pays an annual dividend of $0.29 per share and currently has a dividend yield of 1.78%. The dividend payout ratio of Astellas Pharma is 30.21%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Astellas Pharma will have a dividend payout ratio of 19.08% next year. This indicates that Astellas Pharma will be able to sustain or increase its dividend.
View Astellas Pharma's dividend history.

When did Astellas Pharma's stock split? How did Astellas Pharma's stock split work?

Astellas Pharma's stock split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were issued to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of Astellas Pharma stock prior to the split would have 125 shares after the split.

Are investors shorting Astellas Pharma?

Astellas Pharma saw a decline in short interest in the month of December. As of December 31st, there was short interest totaling 40,400 shares, a decline of 34.0% from the December 15th total of 61,200 shares. Based on an average trading volume of 263,900 shares, the short-interest ratio is currently 0.2 days.
View Astellas Pharma's Short Interest
.

Who are some of Astellas Pharma's key competitors?

Who are Astellas Pharma's key executives?

Astellas Pharma's management team includes the following people:
  • Mr. Kenji Yasukawa Ph.D., Pres, CEO & Representative Director (Age 61)
  • Mr. Naoki Okamura, Exec. VP, CFO & Representative Director
  • Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.
  • Ms. Linda Friedman, Gen. Counsel & VP
  • Mr. Stig Ogata, VP of Corp. Communications
  • Ms. Collette Taylor, Sr. VP of HR (Age 58)
  • Chihiro Yokota, Sr. Corp. Exec. and Head of Japan/Asia Devel., Devel.
  • Dr. Charlotte M. E. Kremer M.D., Mba, Head of Medical Affairs & Exec. VP
  • Mr. Songlin Xue M.D., Ph.D., Head of Pharmacovigilance
  • Akihiko Iwai, Pres of Drug Discovery Research & Sr. Corp. Exec.

What is Astellas Pharma's stock symbol?

Astellas Pharma trades on the OTCMKTS under the ticker symbol "ALPMY."

How do I buy shares of Astellas Pharma?

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Astellas Pharma's stock price today?

One share of ALPMY stock can currently be purchased for approximately $16.56.

How big of a company is Astellas Pharma?

Astellas Pharma has a market capitalization of $30.83 billion and generates $11.97 billion in revenue each year. The company earns $1.80 billion in net income (profit) each year or $0.96 on an earnings per share basis. Astellas Pharma employs 15,883 workers across the globe.

What is Astellas Pharma's official website?

The official website for Astellas Pharma is www.astellas.com.

How can I contact Astellas Pharma?

Astellas Pharma's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.